Merck and Glenmark settle patent litigation on Zetia
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals can launch its generic version of Merck & Co's hypercholesterolaemia treatment, Zetia (ezetimibe), by 12 December 2016, as part of a settlement reached between the two companies over patent litigation concerning the product.